Opinion|Videos|January 28, 2025
Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice
Panelists discuss how patient-specific factors including age, comorbidities, genetic profile, and treatment goals guide the selection between doublet and triplet regimens in chronic lymphocytic leukemia (CLL), with considerations like Bruton tyrosine kinase inhibitor tolerability, desire for time-limited therapy, and high-risk features informing the choice between various BTK inhibitor–based combinations with venetoclax and obinutuzumab.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- For which patients would you consider a doublet vs triplet combination regimen? What factors would you consider among selecting the various triplet regimens (eg, acalabrutinib vs zanubrutinib vs pirtobrutinib plus venetoclax and obinutuzumab)?
Advertisement
Related to this article
FDA has granted fast track designation to LYT-200 plus a hypomethylating agent in relapsed/refractory high-risk myelodysplastic syndromes.
Toon Van Gorp, MD, PhD, discusses key data with TUB-040 in platinum-resistant ovarian cancer and next steps for development.
Japan approved subcutaneous pembrolizumab and berahyaluronidase alfa across all indications for which intravenous pembrolizumab is approved in the country.
New research reveals how cancers carrying mutations in the p53 tumor-suppressor protein can hide those mutations from T cells.
Elise A. Chong, MD, discusses real-world liso-cel efficacy and safety, outpatient use, and future directions in relapsed/refractory mantle cell lymphoma.
Brad S. Kahl, MD, discusses TRIANGLE and EA4151 data reshaping ASCT use in frontline MCL, induction intensity, and high-risk disease strategies.
Mary Ann Anderson, MBBS, FRACP, FRCPA, PhD, discusses recent CLL approvals, BTK and BCL-2 inhibitor safety, and individualizing frontline therapy.
The top 5 OncLive TV videos of the week cover insights in NSCLC, large granular lymphocytic leukemia, ovarian cancer, and myelofibrosis.
Advertisement
Advertisement
Trending on OncLive
1
CLL Treatment Individualization Prompts Changes in Patient Evaluation and Care
2
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
3
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
4
Integrating Bispecific Antibodies Into Frontline Therapy for Newly Diagnosed Multiple Myeloma
5